3990-59-8

Basic information

• Product Name: 1-(3,4-DIHYDRO-2H-CHROMEN-2-YL)METHANAMINE
• Synonyms: 1-(3,4-DIHYDRO-2H-CHROMEN-2-YL)METHANAMINE;(chroMan-2-yl)MethanaMine;2-(aminomethyl)chromane;3,4-dihydro-2H-chromen-2-ylmethanamine
• CAS NO: 3990-59-8
• Molecular Formula: C₁₀H₁₃NO
• Molecular Weight: 163.22
• Mol File: 3990-59-8.mol
• Article Data: 20

Chemical Properties

• Boiling Point: 279.0±9.0 °C(Predicted)
• Appearance: /
• Density: 1.073±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C(protect from light)
• PKA: 9.14±0.29(Predicted)
• CAS DataBase Reference: 1-(3,4-DIHYDRO-2H-CHROMEN-2-YL)METHANAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(3,4-DIHYDRO-2H-CHROMEN-2-YL)METHANAMINE(3990-59-8)
• EPA Substance Registry System: 1-(3,4-DIHYDRO-2H-CHROMEN-2-YL)METHANAMINE(3990-59-8)

Safety Data

• Hazardous Substances Data: 3990-59-8(Hazardous Substances Data)

Usage

Description

1-(3,4-Dihydro-2H-chromen-2-yl)methanamine, also known as chromane-2-yl methylamine, is a chemical compound characterized by a bicyclic structure and an amine group. It is derived from a chromene ring system and has potential applications in pharmaceuticals due to its structural characteristics and possible biological activities.

Uses

Used in Pharmaceutical Industry:
1-(3,4-Dihydro-2H-chromen-2-yl)methanamine is used as a pharmaceutical compound for its potential biological activities and pharmacological properties. Its unique structure makes it a compound of interest in drug discovery and development.
Used in Organic Synthesis:
1-(3,4-Dihydro-2H-chromen-2-yl)methanamine is used as a building block in organic synthesis and medicinal chemistry, contributing to the creation of new compounds and advancing chemical research.

Upstream product

• 51939-71-0 chroman-2-carboxylic acid 
• 403704-70-1 2-aminomethyl-4-chromanone 
• 77039-78-2 2,3-dihydro-4H-benzopyran-2-carboxylic acid chloride 
• 108-20-3 di-isopropyl ether 
• 100-46-9 benzylamine 
• 7732-18-5 water 
• 3990-58-7 chroman-2-ylcarboxamide 

Downstream Products

• 177975-03-0 N-(5-phenyl-3-pyridylmethyl)-N-(2-chromanyl-methyl)-amine, maleate 
• 177975-58-5 N-(3-phenoxy-benzyl)-N-(2-chromanyl-methyl)-amine, maleate 
• 177975-60-9 N-(4-phenyl-2-pyridylmethyl)-N-(2-chromanyl-methyl)-amine, maleate 

Relevant articles and documents

Novel, broad-spectrum anticonvulsants containing a sulfamide group: Pharmacological properties of (S)- N -[(6-chloro-2,3-dihydrobenzo[1,4]dioxin-2- yl)methyl]sulfamide (JNJ-26489112)

Broad-spectrum anticonvulsants are of considerable interest as antiepileptic drugs, especially because of their potential for treating refractory patients. Such "neurostabilizers" have also been used to treat other neurological disorders, including migraine, bipolar disorder, and neuropathic pain. We synthesized a series of sulfamide derivatives (4-9, 10a-i, 11a, 11b, 12) and evaluated their anticonvulsant activity. Thus, we identified promising sulfamide 4 (JNJ-26489112) and explored its pharmacological properties. Compound 4 exhibited excellent anticonvulsant activity in rodents against audiogenic, electrically induced, and chemically induced seizures. Mechanistically, 4 inhibited voltage-gated Na+ channels and N-type Ca2+ channels and was effective as a K+ channel opener. The anticonvulsant profile of 4 suggests that it may be useful for treating multiple forms of epilepsy (generalized tonic-clonic, complex partial, absence seizures), including refractory (or pharmacoresistant) epilepsy, at dose levels that confer a good safety margin. On the basis of its pharmacology and other favorable characteristics, 4 was advanced into human clinical studies.

ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF

The present application is directed to compounds that are TRPV1 antagonists and have formula (I) wherein variables Ar1, L1, R1, R2, R3, R4, R5, Y1, Y2, and Y3, are as defined in the description, which are useful for treating disorders caused by or exacerbated by vanilloid receptor activity.

CO-THERAPY FOR THE TREATMENT OF EPILEPSY AND RELATED DISORDERS

The present invention is directed to co-therapy for the treatment of epilepsy and related disorders comprising administering to a subject in need thereof, co-therapy with a therapeutically effective amount of a benzo-fused heterocycle sulfamide derivative